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Interaction between rheumatoid arthritis and pregnancy: correlation
of molecular data with clinical disease activity measures
T. Ha¨upl1, M. Østensen2, A. Gru¨tzkau3, G.-R. Burmester1 and P. M. Villiger2
Objective. The factors that induce remission of RA during pregnancy and the relapse occurring after delivery remain an enigma. In a
previous study, we investigated gene-expression profiles of peripheral blood mononuclear cells (PBMC) in patients with RA and
healthy women in late pregnancy and postpartum. Profiles of samples from both groups were similar in late pregnancy with elevated
monocyte and decreased lymphocyte signatures. Postpartum, in RA PBMC the high level of monocyte transcripts persisted. Further increase
was observed in adhesion, migration and signalling processes related to monocytes but also in lymphocytes despite similar clinical activity
due to intensified drug treatment. This prompted us to investigate correlations between clinical parameters of disease activity and
gene profiles.
Methods. Transcriptome data were correlated with RADAI, CRP, monocyte and lymphocyte counts. Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway annotations, monocytes and lymphocytes signatures were used as reference information.
Results. Comparative analysis of PBMC expression profiles from RA patients during and after pregnancy with RADAI and CRP revealed a
correlation of these disease activity parameters predominantly with monocyte transcripts. Genes related to cellular programs of adhesion,
migration and response to infections were upregulated. Comparing clinically active and not-active RA patients postpartum revealed a cluster
of 19 genes that could also identify active disease during pregnancy.
Conclusion. The data suggest that an increase of the RADAI and an elevation of CRP is a consequence of molecular activation of
monocytes. Furthermore, they indicate that molecular activation of T lymphocytes may remain clinically unrecognized postpartum. It is
conceivable that a set of 19 genes may qualify as molecular disease activity marker.
KEY WORDS: Rheumatoid arthritis, Pregnancy, Gene expression, Correlation analysis, Molecular pathways, Biomarkers, Monocyte activation,
Postpartum flare.
Introduction
The remission of rheumatoid arthritis (RA) during pregnancy
occurring in the majority of patients remains an enigma.
Improvement of signs and symptoms during pregnancy is
followed by a relapse after delivery [1].
Recently we have studied gene expression of peripheral blood
mononuclear cells (PBMC) in the third trimester and 24 weeks
after delivery in six patients with RA and in eight age-matched
healthy women (Ha¨upl et al., submitted). Gene-expression profiles
performed by affymetrix analysis revealed an elevated monocyte
and a decreased lymphocyte transcriptome during pregnancy
in healthy women. Postpartum this proportion was inverted.
This may reflect a suppression of the adaptive immune response
as part of the tolerance mechanisms towards the semiallogenic
fetus. The complementary increase of phagocytes during preg-
nancy also found by Crocker et al. [2] suggests compensatory
mechanisms provided by innate immune functions. In RA
patients, the PBMC transcriptome during pregnancy was compar-
able to the one in healthy pregnant women, but it became
activated postpartum with a rise in the level of monocyte and a
concomitant increase in lymphocyte transcripts (Ha¨upl et al.,
submitted).
Traditionally, disease activity in RA is defined by clinical
symptoms. The only objective variable of the commonly used
Disease Activity Score (DAS) is the erythrocyte sedimentation
rate or the acute phase reactant CRP. Recent data clearly
showed that behind improvement of clinical symptoms subclinical
disease activity—for example, progressive joint destruction—
may persist [3, 4]. This constellation prompted a search for
correlations between clinical parameters of RA and expressed
genes and the comparison of the setting during and after
pregnancy.
Patients and methods
Patients and controls
Six patients with RA (fulfilling the ACR criteria [5]) and eight age-
matched healthy women were studied at gestational week 32–34
and 24 weeks postpartum. The study was performed at the
Department of Rheumatology and Clinical Immunology/
Allergology of the University Hospital of Bern after approval
by the institutional review board of Bern and informed patient
consent was obtained. Mean age of pregnant patients was 31
(range 21–38), and of pregnant healthy women 33 (21–40).
Disease activity by the RA Disease Activity Index (RADAI)
was 1.7 (range 0–8.6). Tender and swollen joint count were
3.8 (range 0–10) and 2.7 (range 0–6), respectively. Mean level
of CRP was 20.1mg/l (range 9–52), monocyte counts 0.63 cells/
pl (range 0.41–0.88) and lymphocyte counts 1.91 cells/pl (range
1.28–3.31). During pregnancy the following medications were
allowed: NSAIDs until week 32 of gestation, prednisone
maximum 10mg/day throughout pregnancy, antimalarials and
sulfasalazine. Flares postpartum were treated according to
standard protocols.
RNA isolation and Affymetrix analysis
Gene-expression profiles were determined in PBMC derived from
the patients and the healthy women (ND) during the third
trimester of pregnancy and 24 weeks after delivery and processed
as described (Ha¨upl et al., submitted). Reference data from
different highly purified cell types were used to estimate cell-type
association of each individual gene as described elsewhere
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(Ha¨upl et al., submitted). In brief, after extraction by Qiagen
RNeasy Mini Kit according to the manufacturer’s protocol
(Qiagen, Hilden, Germany), 3g of total RNA were used for
in vitro transcription and biotin-labeling of cRNA (ENZO
Biochem, New York, NY, USA). Total 50g/ml cRNA was
hybridized on HG-U133A GeneChips (Affymetrix, Santa Clara,
CA, USA) for 16 h at 458C, subsequently washed, stained (fluidic
station) and scanned (Hewlett Packard Genearray Scanner,
Affymetrix).
Statistical analysis
Spearman rank correlation was performed for all RA patients
during and after pregnancy between clinical parameters and
expression levels for all genes on the microarray. Cell-type
association scores for individual genes were calculated as
previously defined (Ha¨upl et al., submitted), and compared for
the top 100 genes with best correlation to RADAI, CRP,
monocytes and lymphocytes. Functional association with the
34 KEGG pathways on ‘cell communication’, ‘immune system’,
‘infectious diseases’, ‘signal transduction’, ‘signaling molecules
and interaction’ as well as ‘cell growth and death’ was estimated
by the percentage of genes that revealed a correlation coefficient
of R 0.5. For hierarchical clustering, the Genesis software tool
was applied [6].
Results and discussion
Correlation of molecular data with clinical criteria of
disease activity
Disease activity of RA was absent or very low in the third
trimester in all but one patient. It increased in most patients
after delivery and required immunosuppressive treatment.
Spearman rank correlation was performed for all RA patients
during and after pregnancy comparing clinical parameters
(RADAI, CRP, lymphocyte and monocyte counts) and expression
levels for all genes on the microarray. Each of the top 100 genes
identified for correlation either with RADAI, CRP, monocyte or
lymphocyte blood count revealed coefficients between R¼ 0.99
and 0.63. Scores for association of these genes with the major
blood cell types were calculated based on comparative analysis
of reference signatures for each cell type as described elsewhere
(Ha¨upl et al., submitted). RADAI- and CRP-related gene sets
both displayed a dominant role of monocyte transcripts (mean
score S.E.M; RADAI: 0.16 0.02; CRP: 0.16 0.02) compared
to CD4 T-cell (RADAI: 0.11 0.02; CRP: 0.10 0.02) or
CD19 B-cell transcripts (RADAI: 0.08 0.02; CRP:
0.07 0.02).
The analysis of the data demonstrated for the first time a
correlation between RADAI as well as CRP with monocyte but
not with lymphocyte profiles. Of note, the correlation could be
found despite treatment of patients with different immunosup-
pressive drugs. One might argue that this correlation could be
expected as drugs targeting primarily monocytic functions (e.g.
TNF blocking agents [7], tocilizumab [8]) show a decrease in CRP
levels and clinical signs of inflammation much faster and more
potently than drugs targeting lymphocytes or lymphocyte func-
tions (rituximab, cyclosporin, abatacept). Despite differences in
kinetics lymphocyte inhibition is also effective to repress disease
progression in RA [9–11]. With our current findings of a dominant
monocyte profile in active disease but also a broad panel of
expression changes related to lymphocytes during postpartum
disease reactivation (Ha¨upl et al., submitted), one is tempted to
speculate that a defined molecular profile would perform better in
the prediction of therapeutic efficacy of a given drug than clinical
symptoms.
Correlation with genes of molecular pathways
For functional interpretation, 1822 genes of six relevant
pathway groups with 34 pathways defined in the KEGG
database were investigated. The portion of genes per pathway
was determined that correlated with RADAI, CRP or the
calculated PBMC lymphocyte or monocyte fraction by a
coefficient of R 0.5. Based on this portion, pathways were
ranked all together or for each of the six groups separately
(Table 1).
Genes correlating with the RADAI were associated with
adhesion, leucocyte endothelial migration, infection-related pro-
cesses including TLR signaling and cholera-associated responses
as well as signal transduction in the Notch-, phosphatidylinositol-
and mTOR-signalling pathway. Correlation with CRP revealed
genes also associated with cell adhesion and communication,
responses in infections (cholera, H. pylori) and Notch signalling as
well as genes associated with the hematopoietic lineage, the
complement and coagulation cascade, B-cell receptor and ErbB
signalling.
The monocyte fraction correlated with genes predominantly
associated with infection-related processes, with migration,
ECM interaction, hematopoietic lineage, antigen processing,
Calcium and Notch signalling. The lymphocyte fraction correlated
with genes of the T-cell and B-cell receptor signalling pathway,
with cell growth and death-related gene activity and with the
phosphatidylinositol-, mTOR-, ErbB- and VEGF-signalling
pathways.
Taken together, correlation with functional processes revealed
differences between the four parameters. While RADAI, CRP and
monocyte fraction-related processes focused on adhesion, migra-
tion, response to infections and Notch-signalling, lymphocyte
fractions were predominantly associated with typical lymphoid
receptor signalling pathways, different pathways of the signalling
cascade and cell growth.
As lymphocytes are suppressed during pregnancy (Ha¨upl et al.,
submitted) [12] and increase postpartum, one can speculate that
lymphocytes are unleashed after pregnancy, proliferate and
differentiate, in order to upregulate adaptive immune functions.
In light of the discrepancy that RA patients benefit from
pregnancy with its dominance of phagocytes but flare postpartum
when lymphocyte function is recurring [12] by further increase of
the monocyte dominance, a role of lymphocytes in this process
seems obvious. While expression of lymphocyte marker genes
were not or even negatively correlated with markers of disease
activity, phosphatidylinositol- and mTOR-signalling were corre-
lating with both, PBMC lymphocyte fractions and disease activity
and not with the PBMC monocyte fraction. This suggests that
both signalling processes reflect lymphocyte activation. Targeting
lymphocytes in RA via the mTOR pathway has been discussed
earlier [13]. Genes of the phosphatidylinositol pathway are
involved in many different cellular processes. In our study,
especially expression of phosphoinositide 3-kinases was correlat-
ing with the lymphocyte fraction, kinases that have been
implicated in inflammatory processes of RA including T cells
but also other cell types [14].
Genes differentially expressed in active disease
In a third step of analysis, we addressed the question whether a
discrete panel of genes might serve as molecular disease
activity marker set. A pattern consisting of 19 genes was identified
that reflected disease activity in this cohort of patients. It was
derived by comparative analysis of RA patients postpartum
with high and low disease activity as defined by increased levels of
CRP and/or RADAI. With this gene selection we identified
also one patient with active disease throughout pregnancy and
excluded all other patients as well as all normal controls during
and after pregnancy (Fig. 1). No relevant overlap existed
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with genes identified by others except from members of the HLA
class II and the S100 family [15–18]. The increase of S100 family
members in our study was concordant with results reported by
others [15, 18]. In contrast, HLA expression was found decreased
in RA compared to healthy controls by Bovin et al. [15] and van
der Pouw Kraan et al. [17] using PBMC and PAX gene,
respectively. However, analyses by Lequerre´ et al. [16] support
our findings of increased expression of HLA class II which they
found elevated in non-responders towards infliximab.
Conclusion
Taken together this study provides new insights into the
correlation between gene-expression profiles of PBMC and disease
activity in RA. In our previous analysis (Ha¨upl et al., submitted)
we observed an interesting and unexpected finding. There was
concordance between molecular and clinical disease activity of RA
in the third trimester. However, in spite of low disease activity
under therapy with immunosuppressive drugs postpartum, we
found a consistent difference of gene expression between all RA
patients and all healthy women after delivery. In our correlation
analysis we could identify particular sets of marker genes that can
indicate clinical disease activity, not only postpartum but also
during pregnancy. Nevertheless, prospective studies will have to
prove whether these sets of genes identified as markers of active
RA qualify for quantification of disease activity and eventually
may help to predict disease outcome.
TABLE 1. Correlation of pathway with criteria of disease acitivity and fractions of lympocytes and monocytes
Genes per
pathwaya
Lymphocyte fraction
in PBMC
Monocyte fraction
in PBMC CRP RADAI Meane
3314 617 629 365
370 111 124 62
Genes with correlation coefficient 0.5b
Thereof identified in pathwaysc %d
Rank
group
Rank
all %
Rank
group
Rank
all %
Rank
group
Rank
all %
Rank
group
Rank
all %
Cell communication Adherens junction 75 21.3 4 23 6.7 1 11 12.0 1 4 8.0 1 1 5.8
Tight junction 106 22.6 3 21 5.7 3 17 9.4 2 7 5.7 2 6
Focal adhesion 185 23.2 2 19 6.5 2 14 6.5 4 19 4.9 3 11
Gap junction 89 25.8 1 16 4.5 4 24 7.9 3 13 4.5 4 14
Infectious diseases Cholera 38 15.8 3 28 15.8 1 1 26.3 1 1 5.3 1 8 4.2
Pathogenic E. coli infection 48 18.8 2 27 8.3 2 6 6.3 3 22 4.2 2 16
Epithelial cell signalling in H. pylori infection 63 20.6 1 25 7.9 3 7 14.3 2 3 3.2 3 24
Immune system Leucocyte transendothelial migration 108 21.3 7 24 9.3 2 3 6.5 6 20 7.4 1 3 3.9
Toll-like receptor signalling pathway 87 27.6 5 14 3.4 7 25 6.9 5 17 4.6 2 12
Complement and coagulation cascades 67 11.9 9 33 6.0 4 15 11.9 2 5 4.5 3 15
Fc epsilon RI signalling pathway 74 36.5 3 6 2.7 8 28 8.1 4 11 4.1 4 17
Antigen processing and presentation 85 18.8 8 26 7.1 3 9 5.9 7 24 3.5 5 18
Haematopoietic cell lineage 86 24.4 6 17 14.0 1 2 17.4 1 2 3.5 6 19
B-cell receptor signalling pathway 60 40.0 2 2 5.0 5 19 8.3 3 9 3.3 7 21
Natural killer cell-mediated cytotoxicity 123 29.3 4 11 4.9 6 21 5.7 8 26 3.3 8 23
T-cell receptor signalling pathway 90 48.9 1 1 1.1 9 33 4.4 9 29 1.1 9 31
Signal transduction Notch signalling pathway 39 28.2 6 12 7.7 2 8 10.3 1 6 7.7 1 2 3.9
Phosphatidylinositol signalling system 72 37.5 1 4 5.6 5 18 6.9 5 15 6.9 2 4
mTOR signalling pathway 47 36.2 2 7 2.1 10 31 6.4 6 21 6.4 3 5
Calcium signalling pathway 164 14.6 11 29 8.5 1 4 5.5 8 27 5.5 4 7
Jak-STAT signalling pathway 139 23.0 9 20 5.8 4 16 7.9 3 12 5.0 5 9
VEGF signalling pathway 66 31.8 4 9 3.0 7 27 7.6 4 14 4.5 6 13
Wnt signalling pathway 132 31.1 5 10 6.8 3 10 4.5 9 28 3.0 7 25
ErbB signalling pathway 84 32.1 3 8 4.8 6 22 8.3 2 9 2.4 8 28
TGF- signalling pathway 79 21.5 10 22 1.3 11 32 3.8 10 30 1.3 9 30
MAPK signalling pathway 256 27.7 7 13 2.3 8 29 5.9 7 25 0.4 10 32
Hedgehog signalling pathway 46 23.9 8 18 2.2 9 30 0.0 11 34 0.0 11 33
Signalling molecules Cell adhesion molecules (CAMs) 121 14.0 3 32 6.6 3 13 9.1 1 8 5.0 1 10 3.3
and interaction Cytokine–cytokine receptor interaction 231 14.3 2 31 4.8 4 22 6.9 2 16 3.5 2 20
ECM–receptor interaction 82 14.6 1 29 8.5 1 4 6.1 3 23 2.4 3 27
Neuroactive ligand–receptor interaction 270 6.7 4 34 6.7 2 11 2.6 4 33 2.2 4 29
Cell growth and death p53 signalling pathway 61 26.2 3 15 3.3 2 26 6.6 1 18 3.3 1 22 1.9
Apoptosis 81 37.0 2 5 4.9 1 20 3.7 2 31 2.5 2 26
Cell cycle 105 38.1 1 3 0.0 3 34 2.9 3 32 0.0 3 33
A total of 1822 genes of 6 relevant pathway groups with 34 pathways defined in the KEGG database were correlated with RADAI, CRP and the calculated PBMC lymphocyte or monocyte fraction.
aThe table indicates the numbers of genes that were annotated to each pathway, bthat correlated by Re0.5 cand that were identified in all 34 pathways. dAssociation with each pathway was calculated
as the percentage of genes per pathway that correlated by R0.5. Dominance of association was Ranked based on the percentages either within each group of pathways or for all pathways together.
ePathway groups were sorted by the mean percentages of each group.
FIG. 1. Genes were selected based on differential expression between clinically
active and not-active RA patients postpartum (80% of all pairwise comparisons
increased in active disease). This identified a cluster of 19 genes which separated
by hierarchical clustering not only RA patients post partum but also RA patients
during pregnancy into active and not-active RA patient. Not-active RA patients co-
clustered with healthy women.
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Rheumatology key messages
 Postpartal flares in RA correlated with monocyte activation.
 Molecular programs related to adhesion, migration and response
to infection were activated.
 A biomarker pattern is suggested that indicated disease activity.
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